OMS 1620
Alternative Names: MC2 antagonist therapeutic - OMass Therapeutics; OMS-1620Latest Information Update: 16 Jul 2025
At a glance
- Originator OMass Therapeutics
- Class Small molecules
- Mechanism of Action Melanocortin type 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Congenital adrenal hyperplasia; Cushing syndrome
Most Recent Events
- 14 Jul 2025 Pharmacodynamics data from a preclinical study in Congenital adrenal hyperplasia released by OMass Therapeutics
- 29 Jul 2024 Preclinical trials in Congenital adrenal hyperplasia in United Kingdom (unspecified route) (OMass Therapeutics pipeline, July 2024).
- 29 Jul 2024 Preclinical trials in Cushing syndrome in United Kingdom (unspecified route) (OMass Therapeutics pipeline, July 2024).